$BMY that is already a major player in immuno-oncology with Opidivo, Yervoy vs $GSK  that is still growing Oncology division with drugs like Zejula and Jemperli. While BMY is strictly a bio-pharmaceutical company while GSK is slightly more diversified with the tag of being world's biggest vaccine manufacturer. Which of these two is more lucrative  to you, given that both have approximately the same market cap of about $94B and also about same figure for the revenue too?